
Emapalumab
CAS No. 1709815-23-5
Emapalumab( —— )
Catalog No. M36694 CAS No. 1709815-23-5
Emapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface receptors and activating inflammatory signaling.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 362 | Get Quote |
![]() ![]() |
5MG | 607 | Get Quote |
![]() ![]() |
10MG | 846 | Get Quote |
![]() ![]() |
25MG | 1260 | Get Quote |
![]() ![]() |
50MG | 1684 | Get Quote |
![]() ![]() |
100MG | 2241 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEmapalumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface receptors and activating inflammatory signaling.
-
DescriptionEmapalumab (NI-0501) is a humanized monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH).
-
In VitroEmapalumab (NI-0501) impairs IFNcR1 and IFNc-Receptor-2 (IFNcR2) interaction induced by IFNc at the cell surface.
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1709815-23-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Vallurupalli M, et, al. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019 Nov 21;134(21):1783-1786.?
molnova catalog



related products
-
Tenoxicam
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
-
PTUPB
PTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM.
-
Parecoxib
A potent and selective COX-2 inhibitor; a water-soluble prodrug of valdecoxib.